术后血清癌胚抗原可预测激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌的预后。

Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer.

作者信息

Kavgaci Gozde, Sahin Taha Koray, Muderrisoglu Tugcenur, Ileri Serez, Guven Deniz Can, Aksoy Sercan

机构信息

Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkiye.

Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkiye.

出版信息

Expert Rev Anticancer Ther. 2024 Dec;24(12):1319-1326. doi: 10.1080/14737140.2024.2443009. Epub 2024 Dec 19.

DOI:10.1080/14737140.2024.2443009

PMID:39673491

Abstract

BACKGROUND

The prognostic role of preoperative carcinoembryonic antigen (CEA) in breast cancer is recognized, but the impact of postoperative CEA levels on survival in early breast cancer is uncertain.

RESEARCH DESIGN AND METHODS

We conducted a retrospective study of 921 non-metastatic breast cancer patients treated at anonymized. Patients were categorized as normal (CEA ≤3 µg/L) or elevated (CEA >3 µg/L).

RESULTS

Elevated postoperative CEA levels were associated with shorter disease-free survival (DFS) (median, 174.6 vs. 239.8 months; hazard ratio (HR): 1.80; 95% confidence interval (CI): 1.27-2.56; < 0.001) and overall survival (OS) (median, 174.6 vs. 261.1 months; HR:2.34; 95% CI: 1.59-3.45; < 0.001). Elevated CEA was associated with shorter DFS (median, 174.6 months vs. not reached (NR); HR:2.30; 95% CI: 1.03-5.19; = 0.043) and OS (NR vs. NR; HR: 2.81; 95% CI: 1.06-7.48; = 0.039) in stage 1, shorter DFS (median, 239. 8 vs. 141.1 months; HR: 1.95; 95% CI: 1.28-2.98; = 0.002) and OS (median, 169 vs. 261.1 months; HR: 2.56; 95% CI: 1.6-4.12; < 0.001) in stage 2 and shorter OS (median, 65 vs. 183.1 months; HR: 3.25; 95% CI: 1.19-8.83; = 0.021) in stage 3.

CONCLUSIONS

Elevated postoperative CEA indicates worse DFS and OS in patients with HR-positive/HER2-negative early breast cancer.

摘要

背景

术前癌胚抗原（CEA）在乳腺癌中的预后作用已得到认可，但术后CEA水平对早期乳腺癌患者生存的影响尚不确定。

研究设计与方法

我们对921例接受匿名治疗的非转移性乳腺癌患者进行了回顾性研究。患者被分为正常（CEA≤3μg/L）或升高（CEA>3μg/L）两组。

结果

术后CEA水平升高与无病生存期（DFS）缩短相关（中位数，174.6个月对239.8个月；风险比（HR）：1.80；95%置信区间（CI）：1.27 - 2.56；P<0.001）和总生存期（OS）缩短相关（中位数，174.6个月对261.1个月；HR：2.34；95%CI：1.59 - 3.45；P<0.001）。在Ⅰ期，CEA升高与DFS缩短相关（中位数，174.6个月对未达到（NR）；HR：2.30；95%CI：1.03 - 5.19；P = 0.043）和OS缩短相关（NR对NR；HR：2.81；95%CI：1.06 - 7.48；P = 0.039）；在Ⅱ期，与DFS缩短相关（中位数，239.8个月对141.1个月；HR：1.95；95%CI：1.28 - 2.98；P = 0.002）和OS缩短相关（中位数，169个月对261.1个月；HR：2.56；95%CI：1.6 - 4.12；P<0.001）；在Ⅲ期，与OS缩短相关（中位数，65个月对183.1个月；HR：3.25；95%CI：1.19 - 8.83；P = 0.021）。